NASDAQ:ENDP - Endo International Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $3.00
Forecasted Upside: 383.87 %
Number of Analysts: 4
Breakdown:
2 Sell Ratings
1 Hold Ratings
1 Buy Ratings
0 Strong Buy Ratings

^$0.62 As of 05/18/2022 05:00 PM ET

▼ -0.54 (-46.55%)

1 month | 3 months | 12 months

Get New Endo International Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for ENDP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ENDP

^$3.00

▲ +383.87% Upside Potential

This price target is based on 4 analysts offering 12 month price targets for Endo International in the last 3 months. The average price target is $3.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 383.87% upside from the last price of $0.62.

Current Consensus is Hold

The current consensus among 4 investment analysts is to hold stock in Endo International. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
3 buy ratings
1 hold ratings
3 sell ratings

Ratings as of

11/25/2020

0 strong buy ratings
2 buy ratings
2 hold ratings
3 sell ratings

Ratings as of

2/23/2021

0 strong buy ratings
2 buy ratings
2 hold ratings
4 sell ratings

Ratings as of

5/24/2021

0 strong buy ratings
1 buy ratings
2 hold ratings
3 sell ratings

Ratings as of

8/22/2021

0 strong buy ratings
1 buy ratings
2 hold ratings
3 sell ratings

Ratings as of

11/20/2021

0 strong buy ratings
1 buy ratings
1 hold ratings
3 sell ratings

Ratings as of

2/18/2022

0 strong buy ratings
1 buy ratings
1 hold ratings
2 sell ratings

Ratings as of

4/19/2022

0 strong buy ratings
1 buy ratings
1 hold ratings
2 sell ratings

Ratings as of

5/19/2022

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/9/2022	BMO Capital Markets	Lower Price Target		$4.00 ➝ $2.00	High
5/9/2022	Barclays	Lower Price Target		$2.00 ➝ $1.00	High
5/6/2022	Piper Sandler	Downgrade	Neutral ➝ Underweight	$3.00 ➝ $1.00	Low
3/9/2022	Citigroup	Lower Price Target	Buy	$11.00 ➝ $6.00	High
3/3/2022	BMO Capital Markets	Lower Price Target		$8.00 ➝ $4.00	High
3/2/2022	Piper Sandler	Lower Price Target	Neutral	$5.00 ➝ $3.00	High
3/2/2022	Barclays	Downgrade	Equal Weight ➝ Underweight	$5.00 ➝ $2.00	High
12/16/2021	Barclays	Lower Price Target	Equal Weight	$7.00 ➝ $5.00	High
8/31/2021	Piper Sandler	Downgrade	Overweight ➝ Neutral	$10.00 ➝ $3.00	Medium
8/9/2021	Royal Bank of Canada	Lower Price Target	Sector Perform	$6.00 ➝ $5.00	Medium
5/17/2021	Citigroup	Boost Price Target	Buy	$10.00 ➝ $11.00	Low
4/7/2021	Royal Bank of Canada	Initiated Coverage	Sector Perform	$7.00	High
3/8/2021	Barclays	Boost Price Target	Positive ➝ Equal Weight	$6.00 ➝ $7.00	High
3/4/2021	Citigroup	Lower Price Target		$11.00 ➝ $10.00	High
3/3/2021	Morgan Stanley	Boost Price Target	Underweight	$5.00 ➝ $7.00	High
2/8/2021	SVB Leerink	Reiterated Rating	Market Perform		Low
1/19/2021	Citigroup	Boost Price Target		$7.00 ➝ $9.00	High
1/4/2021	Piper Sandler	Boost Price Target	Overweight	$6.00 ➝ $12.00	N/A
11/12/2020	Morgan Stanley	Boost Price Target	Underweight	$3.00 ➝ $4.00	Medium
10/9/2020	Piper Sandler	Boost Price Target	Overweight	$5.00 ➝ $6.00	High
7/27/2020	The Goldman Sachs Group	Initiated Coverage	Sell	$3.00	High
7/8/2020	SunTrust Banks	Reiterated Rating	Buy		High
6/11/2020	Royal Bank of Canada	Reiterated Rating	Hold	$6.00	Medium
5/10/2020	Royal Bank of Canada	Reiterated Rating	Hold	$6.00	Low
4/24/2020	Citigroup	Initiated Coverage	Buy	$7.00	High
4/15/2020	Piper Sandler	Lower Price Target	Overweight	$7.00 ➝ $6.00	Medium
4/2/2020	Royal Bank of Canada	Reiterated Rating	Hold	$6.00	Low
4/2/2020	Morgan Stanley	Lower Price Target	Underweight	$4.00 ➝ $3.00	Low
1/3/2020	Piper Jaffray Companies	Upgrade	Neutral ➝ Overweight	$5.00 ➝ $7.00	Low
8/9/2019	Morgan Stanley	Set Price Target	Sell	$2.00	N/A
8/8/2019	Royal Bank of Canada	Reiterated Rating	Hold	$6.00	High
8/7/2019	Mizuho	Reiterated Rating	Hold	$6.00	High
7/31/2019	Mizuho	Reiterated Rating	Hold	$6.00	High
7/15/2019	Morgan Stanley	Downgrade	Equal Weight ➝ Underweight	$8.00 ➝ $3.00	Medium
7/11/2019	Royal Bank of Canada	Downgrade	Outperform ➝ Sector Perform	$11.00 ➝ $6.00	High
6/17/2019	Citigroup	Downgrade	Buy ➝ Neutral	$19.00 ➝ $5.00	Medium
6/12/2019	Cantor Fitzgerald	Lower Price Target	Neutral	$18.00 ➝ $4.75	High
6/11/2019	Barclays	Initiated Coverage	Equal Weight ➝ Equal Weight	$6.00	High
5/14/2019	Mizuho	Set Price Target	Hold	$9.00	Low
5/13/2019	JPMorgan Chase & Co.	Downgrade	Neutral ➝ Underweight	$9.00	High
3/27/2019	Gabelli	Reiterated Rating	Hold		Medium
3/19/2019	SunTrust Banks	Initiated Coverage	Buy ➝ Buy	$13.00	Medium
3/18/2019	JPMorgan Chase & Co.	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $10.00	Low
3/5/2019	SVB Leerink	Downgrade	Outperform ➝ Market Perform		Low
3/1/2019	Piper Jaffray Companies	Reiterated Rating	Hold		High
11/26/2018	Mizuho	Lower Price Target	Neutral	$15.00	High
11/9/2018	Cowen	Reiterated Rating	Hold	$9.00	Low
10/19/2018	Cantor Fitzgerald	Boost Price Target	Neutral ➝ Neutral	$12.00 ➝ $18.00	Low
9/11/2018	The Goldman Sachs Group	Upgrade	Sell ➝ Neutral	$14.00 ➝ $15.00	Low
8/17/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$7.00 ➝ $17.00	Low
8/14/2018	Mizuho	Boost Price Target	Neutral	$17.00	Low
8/13/2018	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$26.00	High
8/10/2018	BMO Capital Markets	Boost Price Target	Market Perform ➝ Market Perform	$9.00 ➝ $16.00	Low
8/9/2018	SVB Leerink	Boost Price Target	Outperform ➝ Market Perform	$12.00 ➝ $18.00	High
8/9/2018	Stifel Nicolaus	Boost Price Target	Hold ➝ Hold	$10.00 ➝ $17.00	Low
8/9/2018	Citigroup	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $19.00	Low
8/8/2018	Cantor Fitzgerald	Set Price Target	Hold	$12.00	High
8/7/2018	B. Riley	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $15.00	Low
7/23/2018	Cantor Fitzgerald	Set Price Target	Hold	$12.00	Medium
7/18/2018	Deutsche Bank Aktiengesellschaft	Set Price Target	Buy	$11.00	Low
7/11/2018	Citigroup	Reiterated Rating	Buy		Low
6/28/2018	B. Riley	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $13.00	High
6/27/2018	Citigroup	Upgrade	Neutral ➝ Buy	$11.00	High
6/1/2018	Deutsche Bank Aktiengesellschaft	Set Price Target	Buy	$10.00	Medium
5/13/2018	Oppenheimer	Reiterated Rating	Hold		Low
5/8/2018	Cantor Fitzgerald	Set Price Target	Hold	$7.00	High
4/4/2018	Mizuho	Downgrade	Buy ➝ Neutral	$12.00 ➝ $7.00	High
3/10/2018	Barclays	Set Price Target	Hold	$9.00	Low
3/5/2018	BMO Capital Markets	Lower Price Target	Market Perform ➝ Market Perform	$10.00 ➝ $9.00	High
2/28/2018	Gabelli	Downgrade	Buy ➝ Hold		High
2/27/2018	Oppenheimer	Reiterated Rating	Hold		High
2/27/2018	Cantor Fitzgerald	Set Price Target	Hold	$7.00	Low
2/26/2018	JMP Securities	Downgrade	Outperform ➝ Market Perform		Low
2/23/2018	Barclays	Lower Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $10.00	High
2/14/2018	B. Riley	Initiated Coverage	Buy ➝ Buy	$10.00	High
1/11/2018	Cantor Fitzgerald	Set Price Target	Hold	$7.00	Low
1/3/2018	Mizuho	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $12.00	High
1/2/2018	SVB Leerink	Initiated Coverage	Outperform ➝ Outperform	$12.00	High
12/12/2017	Guggenheim	Initiated Coverage	Neutral ➝ Neutral	$8.50	Low
11/10/2017	Piper Jaffray Companies	Reiterated Rating	Hold	$7.00	N/A
11/10/2017	Mizuho	Reiterated Rating	Buy		N/A
11/10/2017	BMO Capital Markets	Lower Price Target	Market Perform	$11.00 ➝ $10.00	N/A
11/10/2017	Cantor Fitzgerald	Lower Price Target	Neutral	$9.00 ➝ $7.00	N/A
11/10/2017	Citigroup	Lower Price Target	Neutral	$9.00 ➝ $7.00	N/A
11/10/2017	Royal Bank of Canada	Lower Price Target	Sector Perform ➝ Sector Perform	$9.00 ➝ $8.00	N/A
10/30/2017	Cantor Fitzgerald	Set Price Target	Hold	$9.00	N/A
10/17/2017	Royal Bank of Canada	Set Price Target	Hold	$9.00	N/A
9/28/2017	The Goldman Sachs Group	Initiated Coverage	Sell ➝ Sell	$7.00	High
9/17/2017	Piper Jaffray Companies	Reiterated Rating	Hold	$9.00	Medium
9/12/2017	Mizuho	Reiterated Rating	Buy	$19.00 ➝ $14.00	Low
8/11/2017	BMO Capital Markets	Reiterated Rating	Market Perform	$15.00 ➝ $11.00	Low
8/10/2017	Morgan Stanley	Lower Price Target	Equal Weight	$12.00 ➝ $8.00	Low
8/10/2017	Cowen	Reiterated Rating	Hold	$16.00	High
8/10/2017	Citigroup	Reiterated Rating	Neutral	$14.00 ➝ $11.00	High
8/10/2017	Mizuho	Reiterated Rating	Buy	$19.00	High
8/10/2017	Royal Bank of Canada	Set Price Target	Hold	$15.00 ➝ $9.00	High
8/9/2017	Deutsche Bank Aktiengesellschaft	Set Price Target	Buy	$15.00 ➝ $13.00	Low
8/9/2017	Royal Bank of Canada	Reiterated Rating	Sector Perform	$15.00 ➝ $9.00	High
8/8/2017	Oppenheimer	Reiterated Rating	Hold		High
8/8/2017	Cantor Fitzgerald	Set Price Target	Hold	$12.00 ➝ $9.00	Medium
7/23/2017	Oppenheimer	Reiterated Rating	Hold		High
7/16/2017	Royal Bank of Canada	Set Price Target	Hold	$15.00	Medium
7/7/2017	Deutsche Bank Aktiengesellschaft	Lower Price Target	Buy	$18.00 ➝ $15.00	Medium
6/17/2017	Guggenheim	Initiated Coverage	Hold	$12.00	Medium
6/16/2017	Cantor Fitzgerald	Initiated Coverage	Neutral ➝ Neutral	$12.00	Low
6/14/2017	William Blair	Reiterated Rating	Market Perform		Low
6/12/2017	Royal Bank of Canada	Set Price Target	Hold	$15.00	Low
6/9/2017	Stifel Nicolaus	Downgrade	Buy ➝ Hold	$22.00 ➝ $15.00	High
6/8/2017	Oppenheimer	Reiterated Rating	Hold		High
5/25/2017	Mizuho	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $19.00	Low

(Data available from 5/19/2017 forward)

News Sentiment Rating

-0.01 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

4 very positive mentions
5 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

10/21/2021

12 very positive mentions
16 positive mentions
3 negative mentions
0 very negative mentions

Mentions as of

11/20/2021

5 very positive mentions
5 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

12/20/2021

10 very positive mentions
13 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

1/19/2022

1 very positive mentions
8 positive mentions
3 negative mentions
0 very negative mentions

Mentions as of

2/18/2022

5 very positive mentions
9 positive mentions
4 negative mentions
1 very negative mentions

Mentions as of

3/20/2022

1 very positive mentions
9 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

4/19/2022

4 very positive mentions
16 positive mentions
14 negative mentions
1 very negative mentions

Mentions as of

5/19/2022

Current Sentiment

Recent Stories by Sentiment

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

Today's Range

Now: $0.62

$0.36

$1.14

50 Day Range

MA: $2.17

$1.10

$2.74

52 Week Range

Now: $0.62

$0.36

$7.07

Volume

55,135,161 shs

Average Volume

5,403,053 shs

Market Capitalization

$145.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.07

Frequently Asked Questions

What sell-side analysts currently cover shares of Endo International?: The following Wall Street research analysts have issued reports on Endo International in the last twelve months: Barclays PLC, BMO Capital Markets, Citigroup Inc., Piper Sandler, Royal Bank of Canada, StockNews.com, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for ENDP.
What is the current price target for Endo International?: 0 Wall Street analysts have set twelve-month price targets for Endo International in the last year. Their average twelve-month price target is $3.00, suggesting a possible upside of 383.9%.
View the latest price targets for ENDP.
What is the current consensus analyst rating for Endo International?: Endo International currently has 2 sell ratings, 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ENDP, but not buy more shares or sell existing shares.
View the latest ratings for ENDP.
What other companies compete with Endo International?: Other companies that are similar to Endo International include Johnson & Johnson, Pfizer, Eli Lilly and, AbbVie, Merck & Co., Inc., Bristol-Myers Squibb, Zoetis, Royalty Pharma, Horizon Therapeutics Public, Jazz Pharmaceuticals, Perrigo, Pacira BioSciences, Corcept Therapeutics, Supernus Pharmaceuticals and Nektar Therapeutics. Learn More about companies similar to Endo International.
How do I contact Endo International's investor relations team?: Endo International's physical mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The company's listed phone number is (531) 268-2000 and its investor relations email address is [email protected] The official website for Endo International is www.endo.com. Learn More about contacing Endo International investor relations.

NASDAQ:ENDP - Endo International Stock Price Target and Predictions

Analyst Price Target for ENDP

Current Consensus is Hold

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

-0.01 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Endo International?

What is the current price target for Endo International?

What is the current consensus analyst rating for Endo International?

What other companies compete with Endo International?

How do I contact Endo International's investor relations team?